High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease
View abstract on PubMed
Summary
This summary is machine-generated.High residual platelet reactivity (HRPR) after clopidogrel loading significantly increases cardiac death and stent thrombosis risk in unprotected left main disease (ULMD) patients receiving drug-eluting stents (DES). Routine platelet reactivity assessment is recommended for guiding patient care.
Area Of Science
- Cardiology
- Interventional Cardiology
- Pharmacology
Background
- Limited data exist on the long-term clinical impact of high residual platelet reactivity (HRPR) following clopidogrel loading in patients with unprotected left main disease (ULMD) undergoing drug-eluting stent (DES) implantation.
- Unprotected left main disease (ULMD) represents a high-risk subset of coronary artery disease requiring careful management.
Purpose Of The Study
- To investigate the association between HRPR after clopidogrel loading and long-term clinical outcomes, specifically cardiac mortality and stent thrombosis, in patients with ULMD treated with DES.
- To identify HRPR as a potential predictor of adverse events in this patient population.
Main Methods
- Prospective assessment of platelet reactivity using light transmittance aggregometry after a 600 mg clopidogrel loading dose in consecutive patients undergoing percutaneous coronary intervention for ULMD.
- Evaluation of cardiac mortality (primary endpoint) and stent thrombosis (secondary endpoint) over a median follow-up of 19.3 months.
- Statistical analysis, including stepwise regression, to determine independent predictors of clinical events.
Main Results
- The incidence of HRPR was 18.6% among 215 patients treated with DES for ULMD.
- Patients with HRPR exhibited significantly higher 3-year cardiac mortality (28.3% vs. 8.0%, P=0.005) and stent thrombosis rates (16.0% vs. 4.2%, P=0.021) compared to those with low residual platelet reactivity (LRPR).
- HRPR was identified as the sole independent predictor of both cardiac death (HR 3.82) and stent thrombosis (HR 3.69).
Conclusions
- High residual platelet reactivity (HRPR) after clopidogrel loading is a robust marker for elevated risk of cardiac death and DES thrombosis in ULMD patients.
- Routine in vitro assessment of platelet reactivity post-clopidogrel loading should be considered in ULMD patients undergoing DES implantation to inform clinical decision-making and potentially optimize patient management.